{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T08:10:14Z","timestamp":1793693414493,"version":"4.5.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T00:00:00Z","timestamp":1751673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T00:00:00Z","timestamp":1751673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/s40001-025-02850-7","type":"journal-article","created":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T01:28:44Z","timestamp":1751678924000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-world experience of hetrombopag in immune thrombocytopenia treatment: a retrospective cohort study"],"prefix":"10.1186","volume":"30","author":[{"given":"Dan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongmin","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Quan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,5]]},"reference":[{"key":"2850_CR1","doi-asserted-by":"publisher","first-page":"2119043","DOI":"10.1080\/21645515.2022.2119043","volume":"18","author":"Y Feng","year":"2022","unstructured":"Feng Y, Quan Y, Cassady K, Zou Z, Gao Y, Zhang X. Clinical characteristics in immune thrombocytopenia patients after COVID-19 vaccination. Hum Vaccin Immunother. 2022;18:2119043.","journal-title":"Hum Vaccin Immunother"},{"key":"2850_CR2","doi-asserted-by":"publisher","first-page":"101777","DOI":"10.1016\/j.eclinm.2022.101777","volume":"56","author":"Y Wang","year":"2023","unstructured":"Wang Y, Sheng L, Han F, Guo Q, Zhang Z, Hou Y, Feng Q, Zhou H, Ji X, Peng J, et al. Efficacy and safety of treatments in newly diagnosed adult primary immune thrombocytopenia: a systematic review and network meta-analysis. EClinicalMedicine. 2023;56:101777.","journal-title":"EClinicalMedicine"},{"key":"2850_CR3","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s12185-018-2445-z","volume":"107","author":"XG Liu","year":"2018","unstructured":"Liu XG, Bai XC, Chen FP, Cheng YF, Dai KS, Fang MY, Feng JM, Gong YP, Guo T, Guo XH, et al. Chinese guidelines for treatment of adult primary immune thrombocytopenia. Int J Hematol. 2018;107:615\u201323.","journal-title":"Int J Hematol"},{"key":"2850_CR4","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3389\/fmed.2020.00110","volume":"7","author":"Y Feng","year":"2020","unstructured":"Feng Y, Xiao Y, Yan H, Wang P, Zhu W, Cassady K, Zou Z, Wang K, Chen T, Quan Y, et al. Sirolimus as rescue therapy for refractory\/relapsed immune thrombocytopenia: results of a single-center, prospective. Single-Arm Study Front Med. 2020;7:110.","journal-title":"Single-Arm Study Front Med"},{"key":"2850_CR5","doi-asserted-by":"publisher","first-page":"901","DOI":"10.2165\/00003495-200868070-00002","volume":"68","author":"R Stasi","year":"2008","unstructured":"Stasi R, Evangelista ML, Amadori S. Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura. Drugs. 2008;68:901\u201312.","journal-title":"Drugs"},{"key":"2850_CR6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40164-021-00214-5","volume":"10","author":"Y Chen","year":"2021","unstructured":"Chen Y, Hu J, Chen Y. Platelet desialylation and TFH cells-the novel pathway of immune thrombocytopenia. Exp Hematol Oncol. 2021;10:21.","journal-title":"Exp Hematol Oncol"},{"key":"2850_CR7","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s40364-024-00700-y","volume":"12","author":"M Yan","year":"2024","unstructured":"Yan M, Wang Z, Qiu Z, Cui Y, Xiang Q. Platelet signaling in immune landscape: comprehensive mechanism and clinical therapy. Biomark Res. 2024;12:164.","journal-title":"Biomark Res"},{"key":"2850_CR8","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/bcpt.12815","volume":"121","author":"L Zheng","year":"2017","unstructured":"Zheng L, Liang MZ, Zeng XL, Li CZ, Zhang YF, Chen XY, Zhu X, Xiang AB. Safety, pharmacokinetics and pharmacodynamics of hetrombopag olamine, a novel TPO-R agonist, in healthy individuals. Basic Clin Pharmacol Toxicol. 2017;121:414\u201322.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2850_CR9","doi-asserted-by":"publisher","first-page":"S2051","DOI":"10.1016\/j.arabjc.2013.07.035","volume":"10","author":"ZJ Jain","year":"2017","unstructured":"Jain ZJ, Gide PS, Kankate RS. Biphenyls and their derivatives as synthetically and pharmacologically important aromatic structural moieties. Arab J Chem. 2017;10:S2051\u201366.","journal-title":"Arab J Chem"},{"key":"2850_CR10","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/cmdc.201200585","volume":"8","author":"C Ballatore","year":"2013","unstructured":"Ballatore C, Huryn DM, Smith AB. Carboxylic acid (Bio)isosteres in drug design. ChemMedChem. 2013;8:385\u201395.","journal-title":"ChemMedChem"},{"key":"2850_CR11","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.drudis.2009.07.014","volume":"14","author":"TJ Ritchie","year":"2009","unstructured":"Ritchie TJ, Macdonald SJF. The impact of aromatic ring count on compound developability\u2014are too many aromatic rings a liability in drug design? Drug Discov Today. 2009;14:1011\u201320.","journal-title":"Drug Discov Today"},{"key":"2850_CR12","doi-asserted-by":"publisher","first-page":"100279","DOI":"10.1016\/j.rpth.2023.100279","volume":"7","author":"Y Hong","year":"2023","unstructured":"Hong Y, Shen Y, Liu Q, Dong J, Xiang J, Shen Y, Wu L, Zhou Y, Ye B, Wu D. Eltrombopag plus cyclosporine in refractory immune thrombocytopenia: a single-center study. Res Pract Thromb Haemost. 2023;7:100279.","journal-title":"Res Pract Thromb Haemost"},{"key":"2850_CR13","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1080\/17474086.2024.2420633","volume":"17","author":"Y Liang","year":"2024","unstructured":"Liang Y, Tang C, Liu C, Zhang L, Fang Y, Zhao A, Chen N. Combination therapy of dexamethasone, rituximab, and cyclosporine for adults with primary immune thrombocytopenia: a prospective observational study. Expert Rev Hematol. 2024;17:855\u201360.","journal-title":"Expert Rev Hematol"},{"key":"2850_CR14","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1007\/s12185-022-03527-1","volume":"117","author":"F Rodeghiero","year":"2023","unstructured":"Rodeghiero F. Recent progress in ITP treatment. Int J Hematol. 2023;117:316\u201330.","journal-title":"Int J Hematol"},{"key":"2850_CR15","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1182\/blood.2021010968","volume":"137","author":"W Ghanima","year":"2021","unstructured":"Ghanima W, Gernsheimer T, Kuter DJ. How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment. Blood. 2021;137:2736\u201344.","journal-title":"Blood"},{"key":"2850_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13045-021-01047-9","volume":"14","author":"H Mei","year":"2021","unstructured":"Mei H, Liu XF, Li Y, Zhou H, Feng Y, Gao GX, Cheng P, Huang RB, Yang LH, Hu JD, et al. A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia. J Hematol OncolJ Hematol Oncol. 2021;14:37.","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"2850_CR17","doi-asserted-by":"publisher","first-page":"3669","DOI":"10.1007\/s00520-016-3297-9","volume":"24","author":"TM Atkinson","year":"2016","unstructured":"Atkinson TM, Ryan SJ, Bennett AV, Stover AM, Saracino RM, Rogak LJ, Jewell ST, Matsoukas K, Li Y, Basch E. The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review. Support Care Cancer. 2016;24:3669\u201376.","journal-title":"Support Care Cancer"},{"key":"2850_CR18","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1111\/jth.15602","volume":"20","author":"H Mei","year":"2022","unstructured":"Mei H, Liu X, Li Y, Zhou H, Feng Y, Gao G, Cheng P, Huang R, Yang L, Hu J, et al. Dose tapering to withdrawal stage and long-term efficacy and safety of hetrombopag for the treatment of immune thrombocytopenia: results from an open-label extension study. J Thromb Haemost. 2022;20:716\u201328.","journal-title":"J Thromb Haemost"},{"key":"2850_CR19","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s12185-021-03149-z","volume":"114","author":"TF Wong","year":"2021","unstructured":"Wong TF, Majewska R, Tomiyama Y. Management of primary immune thrombocytopenia in a real-world setting in Japan: eltrombopag versus corticosteroids. Int J Hematol. 2021;114:152\u201363.","journal-title":"Int J Hematol"},{"key":"2850_CR20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.5045\/br.2015.50.1.19","volume":"50","author":"YK Kim","year":"2015","unstructured":"Kim YK, Lee SS, Jeong SH, Ahn JS, Yang DH, Lee JJ, Kim HJ. Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia. Blood Res. 2015;50:19\u201325.","journal-title":"Blood Res"},{"key":"2850_CR21","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s00277-023-05114-8","volume":"102","author":"D Pulanic","year":"2023","unstructured":"Pulanic D, Batorova A, Bodo I, Cervinek L, Ionita I, Lissitchkov T, Melikyan A, Podolak-Dawidziak M. Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus. Ann Hematol. 2023;102:715\u201327.","journal-title":"Ann Hematol"},{"key":"2850_CR22","first-page":"617","volume":"41","author":"Thrombosis, Hemostasis Group CSoHCMA","year":"2020","unstructured":"Thrombosis, Hemostasis Group CSoHCMA. Chinese guideline on the diagnosis and management of adult primary immune thrombocytopenia (version 2020). Zhonghua Xue Ye Xue Za Zhi. 2020;41:617\u201323.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"2850_CR23","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18864","author":"X Cheng","year":"2023","unstructured":"Cheng X, Wang Z, Dong S, Ma J, Meng J, Wang X, Wu R. Outcomes of switching to avatrombopag following treatment failure with eltrombopag in paediatric immune thrombocytopenia: a real-world study in China. Br J Haematol. 2023. https:\/\/doi.org\/10.1111\/bjh.18864.","journal-title":"Br J Haematol"},{"key":"2850_CR24","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1097\/CM9.0000000000002346","volume":"135","author":"X Cai","year":"2022","unstructured":"Cai X, Fu H, Zhao X, Lu J, Jiang Q, Chang Y, Huang X, Zhang X. Switching between eltrombopag and recombinant human thrombopoietin in patients with immune thrombocytopenia: an observational study. Chin Med J. 2022;135:2344\u201350.","journal-title":"Chin Med J"},{"key":"2850_CR25","first-page":"240","volume":"10","author":"K Mishra","year":"2020","unstructured":"Mishra K, Pramanik S, Jandial A, Sahu KK, Sandal R, Ahuja A, Yanamandra U, Kumar R, Kapoor R, Verma T, et al. Real-world experience of eltrombopag in immune thrombocytopenia. Am J Blood Res. 2020;10:240\u201351.","journal-title":"Am J Blood Res"},{"key":"2850_CR26","doi-asserted-by":"publisher","first-page":"5367","DOI":"10.1111\/jcmm.13809","volume":"22","author":"C Xie","year":"2018","unstructured":"Xie C, Zhao H, Bao X, Fu H, Lou L. Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agonist. J Cell Mol Med. 2018;22:5367\u201377.","journal-title":"J Cell Mol Med"},{"key":"2850_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01401-z","author":"XG Liu","year":"2023","unstructured":"Liu XG, Hou Y, Hou M. How we treat primary immune thrombocytopenia in adults. J Hematol OncolJ Hematol Oncol. 2023. https:\/\/doi.org\/10.1186\/s13045-023-01401-z.","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"2850_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/ange.202505519","author":"D Dibchak","year":"2025","unstructured":"Dibchak D, Mykhailiuk PK. 3-Oxabicyclo[3.1.1] heptane as an Isostere of meta-Benzene. Angew Chem Int Engl. 2025. https:\/\/doi.org\/10.1002\/ange.202505519.","journal-title":"Angew Chem Int Engl"},{"key":"2850_CR29","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1002\/cmdc.201700082","volume":"12","author":"YP Auberson","year":"2017","unstructured":"Auberson YP, Brocklehurst C, Furegati M, Fessard TC, Koch G, Decker A, La Vecchia L, Briard E. Improving nonspecific binding and solubility: bicycloalkyl groups and cubanes as para-Phenyl bioisosteres. ChemMedChem. 2017;12:590\u20138.","journal-title":"ChemMedChem"},{"key":"2850_CR30","doi-asserted-by":"publisher","first-page":"119","DOI":"10.14715\/cmb\/2017.63.11.21","volume":"63","author":"M Sunohara","year":"2017","unstructured":"Sunohara M, Sato I, Morikawa S. Promoter motifs required for c-mpl gene expression induced by thrombopoietin in CMK cells. Cell Mol Biol. 2017;63:119\u201323.","journal-title":"Cell Mol Biol"},{"key":"2850_CR31","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3389\/fendo.2017.00059","volume":"8","author":"LN Varghese","year":"2017","unstructured":"Varghese LN, Defour JP, Pecquet C, Constantinescu SN. The Thrombopoietin receptor: structural basis of traffic and activation by ligand, mutations, agonists, and mutated calreticulin. Front Endocrinol. 2017;8:59.","journal-title":"Front Endocrinol"},{"key":"2850_CR32","doi-asserted-by":"publisher","first-page":"e572","DOI":"10.1038\/bcj.2017.51","volume":"7","author":"M Zingariello","year":"2017","unstructured":"Zingariello M, Sancillo L, Martelli F, Ciaffoni F, Marra M, Varricchio L, Rana RA, Zhao C, Crispino JD, Migliaccio AR. The thrombopoietin\/MPL axis is activated in the Gata1(low) mouse model of myelofibrosis and is associated with a defective RPS14 signature. Blood Cancer J. 2017;7:e572.","journal-title":"Blood Cancer J"},{"key":"2850_CR33","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/nyas.13138","volume":"1375","author":"A Pramono","year":"2016","unstructured":"Pramono A, Zahabi A, Morishima T, Lan D, Welte K, Skokowa J. Thrombopoietin induces hematopoiesis from mouse ES cells via HIF-1alpha-dependent activation of a BMP4 autoregulatory loop. Ann N Y Acad Sci. 2016;1375:38\u201351.","journal-title":"Ann N Y Acad Sci"},{"key":"2850_CR34","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1016\/j.jtha.2024.08.025","volume":"22","author":"P Meng","year":"2024","unstructured":"Meng P, Liu W, Lao J, Liu X, Zhang Y, Sun Y, Zhou R, Du C, Wang J, Zhao D, et al. Paclitaxel improves thrombopoiesis in the absence of thrombopoietin receptor (Mpl). J Thromb Haemost. 2024;22:3599\u2013613.","journal-title":"J Thromb Haemost"},{"key":"2850_CR35","doi-asserted-by":"publisher","first-page":"217264","DOI":"10.1016\/j.canlet.2024.217264","volume":"605","author":"Y Wang","year":"2024","unstructured":"Wang Y, Chang YJ, Chen J, Han M, Hu J, Hu J, Huang H, Lai Y, Liu D, Liu Q, et al. Consensus on the monitoring, treatment, and prevention of leukaemia relapse after allogeneic haematopoietic stem cell transplantation in China: 2024 update. Cancer Lett. 2024;605:217264.","journal-title":"Cancer Lett"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-02850-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-02850-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-02850-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T01:28:45Z","timestamp":1751678925000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-025-02850-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,5]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2850"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-02850-7","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,5]]},"assertion":[{"value":"13 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the Second Affiliated Hospital of Army Medical University (2023\u2013096-1).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"574"}}